Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies. Arvinas entered into a ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier ...

Novartis NVS entered into an exclusive strategic license agreement with a clinical-stage biotechnology company, Arvinas, Inc. ARVN, for the worldwide development and commercialization of the latter’s ...

New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapy Pluvicto significantly ...

Novartis has agreed to license Arvinas’s protein-degradation prostate cancer drug ARV-766. This clinical-stage candidate targets mutated androgen receptors that are thought to confer resistance to ...

The U.S. Food and Drug Administration (FDA) on Friday approved Novartis AG’s (NYSE:NVS) Pluvicto for prostate cancer patients. The expanded indication, which approximately triples the number of ...

A Novartis sign hangs on the side of an office building in Cambridge, Massachusetts. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free ...

In a deal valued at $2.1 billion, Swiss pharma giant Novartis AG will purchase Endocyte, a U.S.-based biopharmaceutical company developing new treatments for prostate cancer. Endocyte focuses on ...

Analysts flagged missing timelines and lingering questions in the JANX007 Phase 1 update. ・Several firms also kept bullish ratings, calling the sell-off disproportionate. ・Retail traders on Stocktwits ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...